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Glycofullerenes as non-receptor 
tyrosine kinase inhibitors- towards 
better nanotherapeutics for 
pancreatic cancer treatment
Maciej Serda1*, Katarzyna Malarz2, Anna Mrozek-Wilczkiewicz2, Marcin Wojtyniak2, 
Robert Musioł1 & Steven A. curley3
The water-soluble glycofullerenes GF1 and GF2 were synthesized using two-step modified Bingel-
Hirsch methodology. Interestingly, we identified buckyballs as a novel class of non-receptor Src kinases 
inhibitors. The evaluated compounds were found to inhibit Fyn A and BTK proteins with IC50 values in 
the low micromolar range, with the most active compound at 39 µM. Moreover, we have demonstrated 
that formation of protein corona on the surface of [60]fullerene derivatives is changing the landscape of 
their activity, tuning the selectivity of obtained carbon nanomaterials towards Fyn A and BTK kinases. 
The performed molecular biology studies revealed no cytotoxicity and no influence of engineered 
carbon nanomaterials on the cell cycle of PANC-1 and AsPC-1 cancer cell lines. Incubation with the 
tested compounds resulted in the cellular redox imbalance triggering the repair systems and influenced 
the changing of protein levels.
Pancreatic cancer is an extremely aggressive type of cancer with a poor prognosis and a five-year survival rate 
of less than 7%1. Moreover, only about 20% of patients are eligible for surgical resection, the only potentially 
curative treatment2. Chemotherapeutic approaches, which are often based on gemcitabine, are still present in the 
clinic as the adjuvant therapy of choice for resected pancreatic cancer. The novel cytotoxic combination strate-
gies and nanoformulations which include Folfirinox and nab-paclitaxel are being developed intensively, but these 
treatments have their own shortcomings and their therapeutic effects are disappointing3. Nanomedical strategies 
which include metallofullerene-based (Gd@C82(OH)22) inhibitors of matrix metalloproteinases (MMPs)4, pho-
tothermally active nanoparticles5,6, and several nanodelivery systems7,8 are also being presented in attempts to 
improve survival in pancreatic cancer patients. At the same time, the pharmaceutical industry has focused sig-
nificant attention around the use of selective tyrosine kinase inhibitors as anti-cancer agents9. The EGFR kinase 
inhibitor Erlotinib has been approved by FDA for use in combination with gemcitabine for locally advanced or 
metastatic pancreatic cancer10. Recently, some reports have suggested that inhibition of non-receptor intracellular 
Src kinases inhibits growth and metastasis of human pancreatic carcinoma in murine models, and is followed 
by synergetic effects in combination therapy with gemcitabine11. In order to overcome the barriers to standard 
chemotherapeutics, we have been exploring the use of [60]fullerene derivatives as novel EPR-targeted nanoth-
erapeutics in in vitro and in vivo models12,13. Previously, we have reported the creation of photoactive and highly 
water-soluble glycofullerene GF2 (termed ‘Sweet-C60’) that predominantly accumulates in the nucleus of pancre-
atic stellate cells (PSCs) and is inherently non-toxic even in high concentrations (above 1 mg/mL)14.
Results and Discussion
Based on the above background, we have synthesized two glycofullerenes: GF1 and GF2 (see Fig. 1A) containing 
D-glucosamine fragments as glycosyl donors in the central core, including full characterization of all intermedi-
ates through MALDI-TOF mass spectroscopy, ESI-mass spectroscopy, 1H- and 13C-NMR, DLS, and zeta potential 
measurements (see Supporting Information, Figs. S1–S5). The Src kinase inhibitory properties for the synthesized 
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glycofullerenes have been thoroughly evaluated, and detailed studies on protein corona formation around the 
glycofullerenes and its influence on selectivity and inhibitory Src kinase activity (see Fig. 1B and Table 1) have 
been carried out. The enzymatic studies of [60]fullerenes have been extended to time-dependent mRNA and 
protein expression analysis for Fyn A and Lck kinases which was performed on two human pancreatic cancer 
cell lines: PANC-1 and AsPC-1. The influence of glycofullerenes on cell cycle regulation as well as induction of 
autophagy in pancreatic cancer cell lines have also been investigated. To the best of our knowledge, this is the first 
work on the use of [60]fullerene nanomaterials as selective non-receptor tyrosine kinases inhibitors.
Previously, we have demonstrated that fluorescently-labelled [60]fullerene derivatives were able to extrav-
asate more into orthotopic murine breast tumor tissues than into the contralateral mammary fat pad13. In this 
study we propose that glycosylation of the [60]fullerene core will promote cancer targeting of engineered car-
bon nanomaterials due to overexpression of glucose transporter membrane proteins (GLUTs) in several cancers, 
including pancreatic adenocarcinoma15. Interestingly, we have performed qRT-PCR experiments on two human 
pancreatic cancer cell lines, showing that AsPC-1 cells present 10 fold higher levels of GLUT-1 mRNAs in com-
parison to PANC-1 cells (see Supporting Information, Fig. S9). We decided to use diserinol malonate (possess-
ing four hydroxyl group) as the second addend attached to our [60]fullerene scaffold. Our previously published 
experiments describing molecular biology impact of compound C60-ser have reported its highly water-soluble 
properties and lack of in vitro cellular and in vivo murine toxicity16,17. Moreover, the metal chelating abilities of 
hydroxyfullerenes have been recently explored, and they should be considered as an important factor modulating 
their interactions with cellular targets, such as enzymes18.
To synthesize the aforementioned structurally diverse glycofullerenes, the modified Bingel-Hirsch methodol-
ogy was applied. The presented synthetic procedure enables the creation of a broad spectrum of [60]fullerenes and 
allows generation of structurally more complicated systems thanks to high synthetic accessibility of functionali-
zation malonates. The [60]fullerene nanomaterials GF1 and GF2 were synthesized in the two-step cyclopropana-
tion reactions, in which [60]fullerene derivative 3 was used as the substrate for the final products (see Supporting 
Information, Fig. S1). The [60]fullerene hexakis-adduct with Th-symmetry (GF1) bearing two or more different 
peripheral functional subunits was obtained in the second Bingel reaction from monoadduct 3 as a starting 
material. The glycofullerene GF2 was obtained as a mixture of regioisomers without further purification, and its 
full chemical characterization had been published earlier14. The MALDI-TOF mass spectrum of peracetylated 
GF1 is shown in Fig. S7 (Supporting Information), showing characteristic molecular peaks for hexakis-adduct 
at 3412 Da. A molecular peak ion from the deprotected sodium adduct GF1 is presented at 2273.2 Da, showing 
also small signals from pentakis isomers at 2026.1 Da (Supporting Information, Fig. S8). As can be seen in Fig. S4 
(Supporting Information), glycofullerene GF1 seems to form aggregates at around 100 nm and shows a surface 
charge of −26.7 mV based on DLS and zeta potential measurements. Mackeyev et al. reported experiments con-
ducted for the water-soluble C60 derivatives, especially those with diserinol units, suggested that those derivatives 
form highly-dynamic aggregates, sized between 100–300 nm in diameter, which exist in equilibrium with free, 
hydrated fullerene molecules (based on SEM studies)19,20. Moreover this equilibrium is connected with addition 
of organic solvents and ionic strength (salts), which complicates understanding of protein corona formation. In 
addition, to better understand formation of glycofullerene aggregates, we performed AFM studies using the Si 
Figure 1. (A) Structures of GF1 and GF2 glycofullerenes; (B) Inhibitory activity of glycofullerenes on a panel 
of non-receptor tyrosine kinases.
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(001) substrate. As one can notice, the substrate was extremely flat, with the roughness, calculated as root mean 
square (RMS), of only 72.8 pm (Fig. S6A). The topography obtained from the AFM shows two types of agglomer-
ates for both glycofullerenes GF1 and GF2. In the case of GF1, the first type consist of separate round-like objects, 
with the average diameter equal to 19.24 nm diameter on average (Fig. S6B), b) larger agglomerates with average 
sizes of 270–300 nm (Fig. S6C). The [60]fullerene derivative GF2 shown in Figs. S6D-E was found to be very 
similar to the previous sample. We have observed two primary types of agglomerates– smaller and larger ones. 
The primary agglomerates were found to have 17.68 nm diameter on average and heights around 10 nm, while 
the larger ones were around 250–280 nm in diameter and height of 400 nm consisting of smaller objects. The 
smaller observed objects were often asymmetric, suggesting that they are formed of even smaller parts (separate 
fullerenes). Unfortunately, due to the size of the AFM tip limiting the image resolution, we were not successful in 
observing those fullerenes. The larger objects however, could be easily distinguished, and were formed of smaller 
agglomerates. Due to protein corona formation on the surface of synthesized glycofullerenes, we were also inter-
ested in the samples dissolved in the DMEM containing FBS, however we have found a huge difficulties in the 
measurements of those samples. The typical result for the FBS containing sample is shown in Fig. S6E. One can 
notice very large structures (tens of µm in diameter), with branch- or leaf-like morphology. Unfortunately, the 
structures were so large, that no glycofullerenes were detected. We have performed a number of experiments with 
diluted samples trying to limit the salt content. The crystal sizes could be diminished, but still no aggregates were 
visible. This could be due to the fact that those aggregates could serve as perfect base for the salt crystals to growth 
from, thus hiding the agglomerates inside.
With a synthetic methodology in hand, we have tested the [60]fullerene nanomaterials as potential inhibitors 
of non-receptor tyrosine kinases including the ABL1, BRK, BTK, and Src family kinases (CSK, Fyn A, Lck, Lyn 
B and Src). As depicted in Table 1, the GF1 compound exhibits inhibitory properties in micromolar ranges, 
modulating the catalytic activity of Fyn A and Lck proteins (IC50 parameters 39.982 and 46.645 µM, respectively). 
Interestingly, almost no inhibitory activity was observed for the ABL1, CSK, Lyn B, and Src kinases. The GF2 
compound shows a relatively high inhibitory activity pattern for Src family kinases, with the exception of the 
CSK protein, and it also presents the lowest value of the IC50 parameter for the Fyn A enzyme (37.307 µM). 
Additionally, this carbon nanomaterial exhibits a high potential of inhibition against the ABL1, BRK, and BTK 
kinases. Due to the lack of water-soluble nanomaterials with inhibitory activity on the Src kinases, a small molec-
ular inhibitor dasatinib has been used as a reference compound in these studies. It presents a nanomolar activity 
on all tested tyrosine kinases, but possesses a low selectivity profile within the tested subgroup of kinases, as well 
as cytotoxic effects on a normal cell line (NHDF)21.
It has been previously reported by experimental and computational approaches that at least 30 proteins may 
interact with [60]fullerenes, including human serum albumins, lysozyme, and HIV proteases22. Based on pleth-
ora of literature reports describing formation of protein corona on the surface of carbon nanomaterials, we have 
decided to carry out inhibition experiments using a cellular medium DMEM containing 12% of fetal bovine serum 
(FBS)23 as a solvent. The DLS measurements (see Supporting Information, Fig. S5) on the GF1 glycofullerene con-
firm that it forms aggregates of around 100 nm that are being rapidly reorganized in the presence of FBS into three 
different subgroups: 8, 30, and 195 nm. The final results of inhibitory activity of C60-FBS complexes are depicted 
in Table 1. As expected, the protein corona formed on the surface of glycofullerenes have modified the landscape 
of their reactivity changing it to higher values of IC50 parameters (Fig. 1B). What is more appealing, the selectivity 
profiles of GF1 and GF2 have been significantly altered. For the GF1 compound, it is inactive towards almost all 
the tested tyrosine kinases with the exception of the Fyn A and BTK kinases with IC50 parameters below 100 µM. 
The GF2 glycofullerene shows the greatest inhibitory activity on Fyn A kinase (IC50 parameter around 100 µM) 
with no activity on ABL1, CSK, Lck, and Lyn B. Although molecular docking studies should also be performed in 
order to analyze the C60-kinases interactions, it can be assumed that glycofullernes do not interact with the active 
site of the aforementioned kinases but rather show an allosteric type of inhibition.
To better understand interactions of fullerene nanomaterials with serum proteins, as well as their inhibitory 
activities on non-receptor kinases, we incubated compound GF2 at two different concentrations (1 and 2 mg per 
mL) with 10% and 100% of FBS. The results are depicted on the Fig. S11 in the Supporting Information. Based on 
the densitometric analysis, we could confirm that the intensities of protein bands around 60, 110 and 160 kDa are 
changed (in comparison to 100% of FBS alone), what is related to the concentration of [60]fullerene nanomate-
rial. Interestingly, when GF2 is incubated with FBS at higher concentration (2 mg/mL), the most increased band 
Compound
IC50 [µM] on tyrosine kinases
ABL1 BRK BTK CSK Fyn A Lck Lyn B Src
GF1 in water* >88.850 51.533 ± 9.329 56.864 ± 12.439 >88.850 39.982 ± 2.665 46.645 ± 3.554 >88.850 >88.850
GF1 in 
DMEM* 940.91 ± 149.711 272.768 ± 46.646 86.184 ± 6.664 320.302 ± 53.310 74.189 ± 20.88 496.224 ± 20.880 710.351 ± 139.494 231.897 ± 46.202
GF2 in water* 40.146 ± 2.028 47.851 ± 3.244 38.929 ± 3.244 >81.103 37.307 ± 3.244 55.961 ± 11.760 62.044 ± 1.216 43.796 ± 1.216
GF2 in 
DMEM* >1000 228.305 ± 60.827 243.714 ± 38.118 933.901 ± 229.16 100.973 ± 17.437 981.346 ± 221.4112 791.565 ± 238.037 491.484 ± 156.123
Dasatinib21** 0.0031 ± 0.0005 0.005 ± 0.0005 0.003 ± 0.0007 0.0013 ± 0.0003 0.0016 ± 0.0008 0.0023 ± 0.0007 0.0012 ± 0.0001 0.0009 ± 0.0001
Table 1. Inhibitory activity of glycofullerenes GF1 and GF2 on non-receptor tyrosine kinases panel performed 
in water and in DMEM with 12% of FBS. *The final concentration of solvents (water, DMEM or DMSO) is 5%. 
**Dasatinib was dissolved in DMSO.
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is that around 65 kDa (it could be associated as bovine serum albumin band, molecular weight around 66 kDa). 
In contrast for the lower concentration studies, one could observe marked increasement of bands for the higher 
mass proteins (110 and 160 kDa). This phenomenon is also observed when the 10% percent FBS studies, and also 
confirmed by other reports in which different nanomaterial concentrations could affect formation of different 
protein coronas24. The obtained experimental results support the hypothesis of protein corona formation around 
synthesized glycofullerene GF2, but further mass spectrometry followed bioinformatic analysis should be carried 
out to identify the exact binding proteins.
The interesting ability of glycofullerenes to inhibit tyrosine kinases in vitro prompted us to evaluate their 
mechanism of action at the cellular level. For this purpose, we have performed an analysis of the transcript and 
the protein levels of Fyn and Lck in the two human pancreatic cell lines after treatment with these glycofullerenes. 
The results of these experiments are presented in Figs. 2 and 3. The qRT-PCR analysis revealed that the GF2 com-
pound caused a significant increase in the expression of FYN after 24-hour incubation in AsPC-1 cells (Fig. 2B). 
In case of PANC-1 cells, we have not observed any statistically significant changes after 24-hour of incubation 
with GF2 (Fig. 2A). In turn, after the next 48 hours we have observed a significant decrease in expression of FYN 
in both tested cell lines. For the GF1 compound, we have noticed a decrease in the level of FYN in PANC-1 cells 
after 24-hour incubation. Then, after the next 48 hours of incubation, the decreased level of FYN are maintained 
in both cell lines. We have observed similar changes in protein levels in both pancreatic cell lines (Fig. 3B). In 
detail, after 24-hours of treatment with GF2 we observed an almost 3-fold increase in the expression of Fyn in 
PANC-1 and AsPC-1 cells. Then, after the next 48 hours, protein levels were dramatically decreased in PANC-1. 
For AsPC-1, we have recorded similar effects but to a lesser extent. Similarly, the decreased expression of Fyn has 
also been registered for the GF1 compound in PANC-1 cells. The time-dependent changes in the expression of 
Fyn at the cellular level could be explained by several factors. The intensified accumulation of this protein may 
be the result of enhanced transcription of the FYN gene. In addition, this effect may be due to the interaction 
of glycofullerenes with a kinase, which may contribute to the inhibition of activity and blocking Fyn protein 
Figure 2. qRT-PCR analysis of expression of FYN and LCK in PANC-1 (A) and AsPC-1 cells (B) after 24-
hour and 72-hour incubation with glycofullerenes (1 mg/mL). The results are shown as the mean ± SD of four 
independent measurements, each in triplicate. Data were analyzed using one-way ANOVA with Bonferroni’s 
post-hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control and respective compounds.
Figure 3. The effect of glycofullerenes (1 mg/mL) on the expression of Fyn, Lck, p21, p53, and HO-1 in 
PANC-1 and AsPC-1 cells (A). Densitometric analyses of these proteins were normalized to GAPDH, 
vinculin, or β-actin. The results are the mean ± SD of three independent experiments. Statistical differences 
were analyzed using one-way ANOVA with a Bonferroni’s post-hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 
compared to the control group and respective compounds (B).
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phosphorylation. In turn, the decrease in the level of protein over time may be indirectly related to its degra-
dation. It should be emphasized that both carbon nanomaterials have shown the highest inhibitory potential 
against Fyn kinase in both water and DMEM medium. In the case of the LCK gene, we have observed the reverse 
behavior after treatment with carbon nanomaterials (Fig. 2). Only the GF1 compound affects changes in the LCK 
level in pancreatic cells. After 24 hours of treatment, we observed a significant increase in the level of this gene in 
PANC-1, while after 72 hours we noticed the opposite situation, namely the level of LCK had decreased in both 
cell lines. It is worth mentioning that the GF1 compound has exhibited greater potential for inhibiting Lck kinase 
(Table 1). However, on the protein level we have recorded a dramatic decrease after 24-hour incubation with GF2 
in PANC-1 cells (Fig. 3B). In other cases, the Lck protein level was undetectable with the use of the Western Blot 
method.
The Fyn and Lck kinases belong to the Src family that plays a crucial role in the signaling networks involved 
in the regulation of various cellular processes, such as proliferation, cell cycle progression, adhesion, migration, 
invasion, and cell survival25–28. With this in mind, we have determined the influence of the tested glycofullerenes 
on the expression of p21 and p53 proteins that are associated with regulation of the cellular proliferation and 
programmed cell death induction (Fig. 3). Interestingly, we have not observed any changes in p53 expression 
in PANC-1. It is noteworthy that AsPC-1 cells possess two mutated p53 alleles, resulting in absence of both 
transcript and protein29. On the other hand, the western blot analysis has revealed influence of glycofullerenes as 
kinase inhibitors on upregulation of p21 protein. In general, we have observed a significant increase of p21 levels 
in AsPC-1 cells after 24-hour incubation with both glycofullerene compounds. We have also recorded increased 
p21 expression in PANC-1 cells after a 24-hour treatment with GF2. These observations are consistent with the 
previous report on the direct relation between inhibition of Fyn and activation of p21 in pancreatic cells26. In 
addition, Jiang et al. demonstrated that inhibition of Fyn activity contributes to phosphorylation of hnRNP E1 
through activation of p21, which affects alternative splicing of integrin β. It is noteworthy that integrins play an 
important role as receptors in the invasion and metastasis of pancreatic cancer cells30. On the other hand, the fact 
that synthesized glycofullerenes did not affect cell cycle arrest in pancreatic cells is surprising (Fig. 4).
We next decided to determine the effect of these carbon nanomaterials on the induction of cell death via 
autophagy. Interestingly, it had been described earlier that NanoC60 nanomaterial had been chemo-sensitizing 
in doxorubicin-resistant HeLa cells via autophagy mediated pathways31. Here, we have performed tests based 
on staining with anti-LC3 Alexa Fluor555 conjugated antibody indicative of autophagy and fluorescence meas-
urement using flow cytometry. The results are presented in Fig. 5. In general, we observed a strong effect on the 
formation of autophagosomes and autophagy induction after a 24-hour treatment with GF2 in both pancreatic 
cancer cell lines that were tested. We have also calculated the autophagy induction ratio by comparison of GF2 to 
control cells, which was 1.9 for PANC-1 and 1.5 for AsPC-1 cells.
Interestingly, these effects were abolished after 48 hours. The possible explanation of these fluctuations could 
be activation of the cellular repair pathways, following an earlier cellular stress response. Luo et al. demonstrated 
Figure 4. Influence of glycofullerenes on the cell cycle progression in pancreatic cell lines. The representative 
histograms from flow cytometry show cell cycle distribution after 24-hour incubation with glycofullerenes (0.1 
and 1 mg/mL) in PANC-1 (A) and AsPC-1 (B) cells. The graph shows the mean ± SD percentage of cells in the 
G0/G1, S, and G2/M phases of the cell cycle from three independent experiments.
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that autophagy may be induced by ROS formation and upregulation of p21 protein32. Additionally, the sustained 
high level of intracellular ROS may cause activation of p38 MAPK kinase and its downstream pathways that 
are involved in cell growth arrest and apoptosis induction specifically in response to oxidative stress33,34. With 
this in mind, we decided to determine the effect of the tested glycofullerenes on the generation of ROS. In this 
purpose, we conducted a series of experiments with different incubation times (9, 12, 24 h) with GF1, GF2 and 
their combination with ROS quencher - Neocuproine (NCP) in PANC-1 and AsPC-1 cells. The concentration of 
ROS were measured using the CellROX fluorescence assay according to protocols established by our group for 
small-molecule compounds35. In general, we observed an increase of ROS levels after incubation with the tested 
glycofullerenes in both cell lines (see Supporting Information, Fig. S10). The highest increase was observed after 
9 h incubation in PANC-1 cells (about 130%) – Fig. S10A. Then, in subsequent incubation time points with GF1 
and GF2, we noticed a slight decrease to 110% in comparison to untreated control. Similarly effect, but to a lesser 
extent, was observed in AsPC-1 cells (Fig. S10B). Moreover, the addition of NCP, which is known ROS scavenger 
and glycofullerenes resulted in decrease ROS concentration below basal level in pancreatic cells. The upregulation 
of autophagy by carbon nanomaterials may also represent an interesting tool to induce cell death in cancer cells.
Heme oxygenase (HO-1) is another oxidative stress marker that may be activated by similar stimuli including 
polyhydroxylated fullerenes36. Under normal conditions, HO-1 expression is low in the majority of cells and tissues. 
Some reports have demonstrated that upregulation of HO-1 is regulated by signaling pathways, in which MAPK 
kinases play a key role37,38. With this in mind, we have evaluated HO-1 levels after 24- and 72-hour treatment with 
glycofullerenes (Fig. 3B). We noticed an almost 7-fold increase in the expression of HO-1 in PANC-1 cells after 
72 hours in both compounds. However, a shorter incubation has no significant effect on the protein level in this cell 
line. Contrarily, we recorded a significant increase for GF1 after 24-hour incubation in AsPC-1 cells. With GF2 we 
observed a very slight increase in HO-1 levels. After a 72-hour incubation, the protein level was undetectable with 
the use of the Western Blot method, which may indicate that redox balance has been recovered.
To conclude, this novel report indicates glycofullerene-based inhibitors of non-receptor tyrosine kinases are 
able to selectively modulate the activity of Fyn A and BTK/Lck proteins. Positive influence of serum proteins 
may suggest that formation of fullerene-protein corona is an important factor in the process of inhibition. The 
performed SDS-PAGE electrophoresis studies confirmed formation of protein corona on glycofullerene GF2. 
Interestingly, the synthesized carbon nanomaterials have been found to be non-toxic, neutral for the pancre-
atic cancer cell cycle, but induces autophagy and disrupts redox balance. This work opens a new avenue in [60]
fullerene-protein biomedical studies and it reflects a significant advancement in developing pancreatic cancer 
nanotherapeutics. Further studies explaining mechanisms of inhibition, especially for the Fyn A and BTK/Lck 
kinases, should be carried out with particular emphasis on determination of the Km and Vmax parameters that are 
crucial for understanding this type of inhibition.
Figure 5. Influence of glycofullerenes (1 mg/mL) on autophagy induction in PANC-1 (A) and AsPC-1 (B) cells. 
The histograms show the autophagy induction ratio that was calculated by comparison of fluorescence from 
control cells (blue or gray peak) to the tested compounds (red peak). As a positive control, Imatinib (25 μM) 
was used. Data were analyzed using one-way ANOVA with Bonferroni’s post-hoc test: *p < 0.05, **p < 0.01, 
***p < 0.001 compared to the control (untreated cells).
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Methods
Synthesis of glycofullerenes GF1 and GF2 and their malonic acid precursors. All compounds 
used were reagent grade or better, solvents were used as received unless otherwise specified. The following rea-
gents were used as received: C60 (99.5+%, SES Research, USA), D-glucosamine hydrochloride (Sigma Aldrich), 
DBU (1,8-diaza-bicyclo[5.4.0]undec-7-ene, Sigma Aldrich), ethyl hydrogen malonate (Sigma Aldrich), 
CBr4 (Sigma Aldrich), 2-amino-1,3-propanediol (AK Scientific), DIC (N,N’-Diisopropylcarbodiimide, 
Sigma Aldrich) and 1-hydroxybenzotriazole monohydrate (Sigma Aldrich). The following reagents: Et3N 
(Acros Organics), acetic anhydride (Fisher), pyridine (Sigma Aldrich) and DMF (Sigma Aldrich) were pre-
pared according to literature procedures by distillation with calcium hydride and used immediately. Nuclear 
magnetic resonance spectra were measured on a Bruker Avance III 500 MHz NMR Spectrometer with TMS as an 
internal standard. MS spectra for water-insoluble compounds were collected using an Autoflex II MALDI-TOF 
mass spectrometer, and for water-soluble [60]fullerene derivatives by an MS electrospray ionization time-of-
flight (ESI-microTOF) mass spectrometer, both instruments from Bruker Daltonics Inc (Fremont, CA). High 
resolution spectra were performed using Shimadzu IT-ToF LC-MS System and flash chromatography was per-
formed using Isolera Flash Purification System The purity of all compounds was assessed using a Agilent1260 
equipped with a DAAD detector at 260 nm, RP-column: Eclipse plus C18 (3,5 μm); flow 0.5 mL/min. The AFM 
experiments were performed using ambient pressure atomic force microscopy (AFM) NanoWizard3 from JPK 
Instruments. The surface topography and morphology were obtained using ultra-sharp tip (1 nm tip apex) well 
suitable for high resolution soft tapping mode. The data was analyzed using Gwyddion package39. The distri-
butions of aggregates sizes were obtained by using masks on the topography maps, calculating the equivalent 
radius of observed.
Synthetic protocol for preparation of two [60]fullerene nanomaterials GF1 and GF2 is depicted on Fig. S1. 
The malonates (1) and (2) as well as glycofullerene GF2 were synthesized according to previously described 
methodology14.
Synthesis of diserinol malonate acetate (3). Diserinol malonate and its peracetylated version were synthesized 
on large scale by the modification of previously published synthetic protocol by Wharton and Wilson40. Briefly, 
2-amino-1,3-propanediol (100 g, 1076 mmol) and dimethyl malonate (57.4 mL, 500 mmol) were dissolved in dry 
isopropanol, heated with vigorous stirring at 50 °C for 30 minutes and then stirred for 14 days at room tempera-
ture, under a nitrogen atmosphere. After that time, the white solid precipitated, was filtered off and washed with 
cold isopropanol. After recrystallization from isopropyl alcohol, the white solid was obtained and dried under 
lyophilization (m.p. 132 °C, yield 92%). Serinol malonate (25.0 g, 99.9 mmol) was suspended in pyridine (100 mL, 
1240 mmol) at 0 °C, to which acetic anhydride (150 mL, 1590 mmol) was added dropwise over the course of an 
hour. After reaching 25 °C, dissolution occurred and the solution was stirred continuously for 48 hours. At 0 °C, 
methanol (50 mL, 1225 mmol) was added to quench remaining acetic anhydride and the solution was stirred 
for 1 hour, whereupon the solvents were removed in vacuo and the residue (yellow oil) was dissolved in dichlo-
romethane and recrystallized over 12 hours in hexane. The precipitate as white crystals was collected by filtration, 
washed with hexanes and dried in vacuo (m.p. 91 °C, lit. 91–92 °C40).
Synthesis of [60]fullerene hexakis adduct (GF1). C60 (720 mg, 1.00 mmol) was dissolved in freshly distilled tolu-
ene (800 mL) with CBr4 (497 mg, 1.5 mmol), and malonate 2 (461 mg, 1 mmol). At 25 °C, 1,8-diazabicyclo[5.4.0] 
undec-7-ene (DBU, 190 mg, 1.25 mmol) in toluene was added and the reaction was allowed to proceed for 3 hours 
at room temperature under a nitrogen atmosphere. Flash chromatography was used (dichloromethane: metha-
nol, 95:5; silica: Mallinckrodt, 75–250 µm particles, 150 Å pore size) to isolate the product. Purified peracylated 
[60]fullerene monoadduct (65 mg, 0.055 mmol) was dissolved in freshly distilled toluene (150 mL) with CBr4 
(365 mg, 1.1 mmol), and peracylated diserinol malonate (230 mg, 0.55 mmol). At 25 °C, 1,8-diazabicyclo[5.4.0] 
undec-7-ene (DBU, 100 mg, 0.66 mmol) in toluene was added slowly during 6 hours, and the reaction was allowed 
to proceed for 36 hours at room temperature under a nitrogen atmosphere. Flash chromatography was used (gra-
dient from dichloromethane: methanol, 95:5 to 50:50; silica gel: Mallinckrodt, 75–250 µm particles, 150 Å pore 
size) to isolate the protected product. Yield: 57 mg (32%). Deprotection of acyl groups was performed in 18 mL 
of 1,4-dioxane with addiction of 2 mL of concentrated hydrochloric acid (36.5%) and then stirred at room tem-
perature for 5 days. After that time, the final product was purified by dialysis of an aqueous solution of 7 using 
a cellulose membrane (molecular weight exclusion limit 1.0 kDa; Spectrum Labs, USA) up to the point where 
electrical conductivity of a purified glycofullerene became nearly equal to the conductivity of distilled water, and 
then lyophilized.
Atomic force microscopy (AfM) studies. The investigated samples of glycofullerenes were transferred 
onto the atomically flat Si (001) surface in a form of small (10 µl) droplets. The droplets contained typically 
0.1 mg/mL of sample mixed with water or the DMEM medium containing 12% FBS. The droplets were left under 
ambient pressure to evaporate excess of water and subsequently measured.
cell cultures. The cell cultures were prepared according to manufactures’ protocols as well as our previously 
developed methodology for anti-cancer agents and [60]fullerene nanomaterials14,21. Briefly, human pancreatic 
cell lines PANC-1 and AsPC-1 were purchased from Sigma Aldrich. The cells were grown as monolayer cultures 
in Dulbecco’s modified Eagle’s medium or RPMI-1640 medium in 75 cm2 flasks (Nunc). DMEM for PANC-1 cells 
was supplemented with 12% heat-inactivated fetal bovine serum (Sigma). RPMI-1640 for AsPC-1 cells was sup-
plemented with 10% heat-inactivated fetal bovine serum. Both media also contained a mix of antibiotics −1% v/v 
of penicillin and streptomycin (Gibco). All of the cell lines were cultured under standard conditions at 37 °C in a 
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humidified atmosphere with 5% CO2. All of the cell lines were subjected to routine mycoplasma testing using the 
PCR technique with specific Mycoplasma primers in order to ensure that there was no contamination.
cytotoxicity assay. Cytotoxicity studies for synthesized glycofullerenes were performed and evaluated 
by the activity of mitochondrial reductases (MTS assay), according to a well-established protocols previously 
described by our group for small-molecules41,42.
non-receptor tyrosine kinases inhibition in vitro. The inhibition of the tyrosine kinases by glycof-
ullerenes were measured using Kinase Selectivity TK-2 profiling system and ADP-Glo assay (both reagents from 
Promega). This methodology was previously developed and described by our group for styrylquinazoline deriv-
atives, and now extended and modified for [60]fullerene nanomaterials21. Before start experiments, the glycof-
ullerenes being tested were dissolved in water or DMEM with 12% FBS to a concentration of 40 mg/mL (stock 
solution), which was used to prepare subsequent solutions in the concentration range of 0.05–2 mg/mL in a 1x 
Kinase Buffer. The results from these assays were presented as the percentage of the inhibition of tested kinases 
after treatment with the various concentrations of GF1 and GF2 nanomaterials. In addition, the inhibitory con-
centration (IC50) values were calculated using GraphPad Prism 7.0 (GraphPad Software, USA, https://www.
graphpad.com).
the mRnA expression of fYn and LcK kinases. A general method for analysis of mRNA expression 
of non-receptor kinases was described by our group for quinazoline derivatives and now extended and mod-
ified for [60]fullerene nanomaterials21. In short, after 24 h or 72 h treatment with tested glycofullerenes, total 
RNA was isolated from the pancreatic cells using TRIzol Reagent (Ambion) according to the supplier’s protocols. 
Single-stranded cDNA was synthesized from 4 μg of total RNA using a SuperScript IV Reverse Transcriptase kit 
with appropriate oligoprimers (dT)20 (both from Invitrogen). The quantitative Real-Time PCR was carried out 
in standard reaction volume of 20 μL, consisting of SsoAdvanced Universal SYBR Green Supermix (Biorad), 
primers mix (0.5 μM) and 1 μL of cDNA in CTX96 Touch Real-Time PCR Detection System (Biorad). The 
qRT-PCR reactions were carried out under the standard conditions: pre-denaturation (95 °C/30 sec), denatur-
ation (95 °C/15 sec), annealing (temperature dependent on primers properties/30 sec), extension (72 °C/60 sec). 
The three last steps were repeated for 40 cycles. Data was interpretation and analyzed using the 2−ΔΔCT method 
as described by Livak and Schmittgen43. The sequences of FYN, LCK and ACTB (reference gene) primers were 
designed in Primer 3 and were bought from Sigma Aldrich (see Table S1).
Basal level of the mRNA expression of GLUT-1 in pancreatic cells. Total RNA was isolated from 
PANC-1 and AsPC-1 cells using TRIzol Reagent (Ambion) according to the manufacturer’s instructions. The 
cDNA synthesis and qRT-PCR reaction were performed as were described above. Target and reference primer 
pair sequences were designed in Primer 3 and were purchased from Sigma Aldrich (Table S2). Data was analyzed 
based on a comparison of the expression of the target genes to a reference gene – GAPDH, using the 2−ΔΔCT 
method. The experiments were performed at least four times.
Western blotting. Immunoblotting experiments were carried out using a well-established protocols previ-
ously described by our group for small-molecules35. Cellular lysates were collected after 24 h or 72 h treatment 
with glycofullerenes (1 mg/mL) in PANC-1 and AsPC-1 cell lines. The quantitation of protein was measured using 
a Micro BCA Protein Assay Kit (Thermo Scientific) according to the supplier’s manuals. The proteins (20 μg) 
were separated on SDS-Page gels and electrotransferred onto 0.2 µm pore-size nitrocellulose membranes. After 
blocking step, the nitrocellulose membranes with proteins were incubated with specific primary antibodies: Fyn, 
Lck, p21, p53, HO-1, vinculin and GAPDH (all diluted 1:1000) overnight, then washed and incubated with horse-
radish peroxidase-conjugated secondary antibodies (1:1000 dilution). All primary and secondary antibodies were 
bought from CellSignaling. Finally, the horseradish peroxidase activity signal were detected using SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific) in ChemiDoc XRS + System (BioRad). The densitio-
metric analysis was performed as described elsewhere35.
cell cycle analysis. Cell cycle analysis was carried out according to a well-established protocols previously 
described by our group for small-molecules35. Briefly, PANC-1 and AsPC-1 cells were seeded according to stand-
ard procedures. Then, freshly prepared solutions of glycofullerenes at 1 mg/mL concentration were added in 3 cm 
Petri dishes (Nunc). The changes of cell cycle of pancreatic cells were determined after a 24 hour treatment with 
tested glycofullerenes using a Muse Cell-Cycle Kit (Millipore) according to the manufacturer’s protocols.
Autophagy induction assay. PANC-1 and AsPC-1 cells were seeded in 96-well plates (Nunc) at a density 
of 20,000 cells/well (for 24 h assay) and 10,000 cells/well (for 48 h assay) and incubated at 37 °C for 24 hours. Then, 
the medium was removed and freshly prepared solutions of glycofullerenes at 1 mg/mL concentration were added 
and the cells were incubated for 24 or 48 hours. As positive control, cells were treated with Imatinib (25 µM) for 
24 hours. After treatment, assays were performed using a MuseAutophagy LC3-antibody based kit (Millipore) 
according to the manufacturer’s instructions. Briefly, cells were collected, washed with cold HBSS and centrifuged 
at 300 g for 5 min. Afterwards, cells were resuspended in 95 μL of 1X Autophagy Reagent B with 5 μL of Anti-LC3 
Alexa Fluor555 antibody and incubated for 30 minutes on ice in the dark. After this time, the cells were centri-
fuged and resuspended in 200 μL of 1X Assay Buffer. Then, the cells immediately were processed for autophagy 
induction analysis using a Muse Cell Analyzer (Millipore). Autophagy induction ratio were calculated based on 
the ratio between the target sample fluorescence versus the control sample. The experiments were performed at 
least three times.
9Scientific RepoRtS |          (2020) 10:260  | https://doi.org/10.1038/s41598-019-57155-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
RoS formation. The ROS measurements were performed according to protocols described previously by 
our group35. In short, PANC-1 and AsPC-1 cells were seeded according to standard procedures. Prior the exper-
iments, the fresh solutions of glycofullerenes at 1 mg/mL concentration were prepared, which were then trans-
ferred into plate and incubated for 9, 12 and 24 hours in a kinetic experiment. For quenching reactive oxygen 
species, Neocuproine at 50 μM concentration was added. The ROS formation was determined using a CellROX 
Green Reagent (Molecular Probes) according to the supplier’s protocols.
protein corona assay. Preparation of protein corona and assessments of nanomaterials interactions with 
FBS proteins were performed according to Strojan et al.44, with some modifications. In short, GF2 glycof-
ullerene was prepared to a final concentration 2 mg/mL or 1 mg/mL in the 100% FBS solution and 1 mg/mL 
in RPMI medium supplemented with 10% FBS. Afterwards, FBS-GF2 mixtures were incubated for 2–3 h in 
37 °C. Then, the samples (FBS-GF2) and control (100% FBS) were centrifuged at 15,000 x g for 20 minutes at 
4 °C, supernatants were removed and pellets were re-suspended in 1 mL cold PBS without CaCl2 and MgCl2. 
This washing procedure was repeated three times to remove non-bounded proteins. After last centrifugation, 
samples were re-suspended in NuPAGE LDS Sample Buffer, then vortexed and heated for 5 min at 95 °C. At 
this stage, FBS-GF2 complexes were broken down, and GF2 were removed by centrifugation at 15,000 × g 
for 20 min. The equal amounts of the remaining proteins, which interacted with glycofullerene were sepa-
rated on SDS-PAGE gels. After electrophoresis, the gels were stained with Coomassie Stain G-250 reagent for 
30 min. The image were acquired using a ChemiDoc XRS + System (BioRad) and densitometric analysis was 
performed as described elsewhere35.
Statistical analysis. Results are expressed as the mean ± standard deviation (SD) from at least three inde-
pendent experiments. Statistical differences in the expression of genes and proteins, autophagy induction and 
progression of cell cycle were calculated using the one-way ANOVA with a Bonferroni post-hoc test. A p-value of 
0.05 or less was considered to be statistically significant. GraphPad Prism 7.0 software (GraphPad Software, USA, 
https://www.graphpad.com) was used for analysis.
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